We are pleased to welcome Ivana Rubino, Ph.D., as our Chief Commercial Officer. Dr. Rubino brings over 15 years of global biopharmaceutical leadership experience, with deep expertise in neuroscience, including Alzheimer’s disease. Learn more here: bit.ly/4AWa42Q

Did you know misfolded proteins can expose disease-specific epitopes (DSEs)? Our EpiSelect™ platform is designed to identify them, supporting development of antibodies that target misfolded toxic proteins while sparing healthy ones. Learn more: bit.ly/4AbmNOM

In September, ProMIS Neurosciences will participate in several healthcare investor conferences to discuss our PRECISE-AD Phase 1b clinical trial in early Alzheimer’s disease and our EpiSelect™ platform. Learn more: bit.ly/46xVnEW

Today, we announced our Q2 2026 financial results and corporate highlights. Read more in our press release: promisneurosciences.com/inve…

We will report our second quarter 2026 financial results and provide a business update on August 13, 2026. Read our full press release for more information: bit.ly/4fUfku1

Today we reported positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of our lead drug candidate, PMN310, in patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD. Learn more: promisneurosciences.com/news…

We will host a webinar on July 28 at 8:00 a.m. ET to discuss upcoming six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in early Alzheimer’s disease. See the press release to learn more and register: bit.ly/4vOg9dX

We are presenting the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by PMN310 at #AAIC2026 today! Read our PR to learn more about the findings and PMN310's differentiated mechanism, targeting toxic AβO’s: promisneurosciences.com/news…

We're looking forward to connecting with the Alzheimer's disease research community at @alzassociation #AAIC2026. Our poster highlights the activity & clinical progress of PMN310, our investigational antibody targeting toxic Aβ oligomers. Connect with us: bit.ly/4wlXG90

This June, ProMIS CEO, Neil Warma, will participate in several conferences to discuss our EpiSelect™ platform and lead Alzheimer’s disease candidate, PMN310, as we approach our PRECISE-AD blinded interim data analysis in early Q3 2026. Learn more: bit.ly/4dBWEzq

Are you attending @LifeSciEvents' #FierceBiotechWeek 2026? Our CEO, Neil Warma, will moderate a panel on the future of neurodegenerative drug development, including combination strategies & earlier intervention. Learn more about the panel here: bit.ly/3PBtyXx #FBW2026

Today, we announced our Q1 2026 financial results and corporate highlights. Read more in our press release: bit.ly/3PcpdtQ

Neurology Today and ANN, thank you for the opportunity to discuss science. Dr. Kaplan said the Abeta vaccine differs from other development because it “is selective for toxic oligomers and does not contain Abeta T-cell epitopes, so it will not stimulate detrimental T cells."

Antibodies that bind selectively to neurotoxic Aβ oligomers potentially  modify the course of the Alzheimer's disease. biospace.com/article/bridgin…

On Nov 14th we shared third quarter 2022 financial results and highlighted recent developments. promisneurosciences.com/inve… #Alzheimers #ENDALZ $PMN

Our #drugdiscovery platform combines #biology, #physics and #supercomputing to neutralize toxic amyloid with a precision that traditional #drugdevelopment tools can't achieve. Data show no monomer distraction. bit.ly/3RUQ7BN #TechTuesday #biotech #ENDALZ

ProMIS has an important point of #differentiation. Our platform enables us to develop #antibodies that are highly selective for toxic misfolded #proteins. #Physics + #Biology + #Supercomputing. $PMN #differentiated #toxicoligomers #misfoldedproteins #neurodegenerativedisease

"Antibodies that target amyloid latch on at slightly different places.” #Lecanemab binds to protofibrils. “...before these chains clump together to form plaques in the brain. It could be that catching the amyloid earlier in the process makes a difference." cnn.it/3rFQPYE

We’re thrilled to announce Dr. Gail Farfel as our CEO. She brings more than 20 years’ experience in #neuropsychiatric clinical development & global regulatory submissions, including multiple successful #IND and #NDA apps & #FDA Advisory experience $PMN bit.ly/3CbURhN

Heartiest congratulations to @EisaiUS , #Biogen, its clinical trial researchers and most importantly, the clinical trial volunteers who committed their time and trust to deliver landmark news for the #Alzheimer's community. ##WorldAlzheimersMonth #ENDALZ bit.ly/3y2yF7k